Comparative Study of Protective Action of Exogenous 2-Cys Peroxiredoxins (Prx1 and Prx2) Under Renal Ischemia-Reperfusion Injury

• Published in: Antioxidants 2020-08, Vol.9 (8), p.680
• Main Authors: Sharapov, Mars G., Goncharov, Ruslan G., Filkov, Gleb I., Trofimenko, Alexander V., Boyarintsev, Valery V., Novoselov, Vladimir I.
• Format: Article
• Language: English
• Subjects: Anemia; Animal models; antioxidant activity; Antioxidants; Cancer; Deoxyribonucleic acid; DNA; Enzymes; Free radicals; Health aspects; Hemoglobin; Injuries; Intravenous administration; Ischemia; ischemia-reperfusion; kidney; Kidneys; Kinases; Macromolecules; Mammals; Molecular weight; Oxidation; Oxidative stress; Peroxide; peroxiredoxin; Physiological aspects; Physiology; Proteins; Reactive oxygen species; Reperfusion; Spleen; Structure-function relationships; Thioredoxin
• ISSN: 2076-3921; 2076-3921
• DOI: 10.3390/antiox9080680

The pathogenesis of ischemia-reperfusion (I/R) injuries is based on oxidative stress caused by a sharp increase in the concentration of free radicals, reactive oxygen species (ROS) and secondary products of free radical oxidation of biological macromolecules during reperfusion. Application of exogenous antioxidants lowers the level of ROS in the affected tissues, suppresses or adjusts the course of oxidative stress, thereby substantially reducing the severity of I/R injury. We believe that the use of antioxidant enzymes may be the most promising line of effort since they possess higher efficiency than low molecular weight antioxidants. Among antioxidant enzymes, of great interest are peroxiredoxins (Prx1–6) which reduce a wide range of organic and inorganic peroxide substrates. In an animal model of bilateral I/R injury of kidneys (using histological, biochemical, and molecular biological methods) it was shown that intravenous administration of recombinant typical 2-Cys peroxiredoxins (Prx1 and Prx2) effectively reduces the severity of I/R damage, contributing to the normalization of the structural and functional state of the kidneys and an almost 2-fold increase in the survival of experimental animals. The use of recombinant Prx1 or Prx2 can be an efficient approach for the prevention and treatment of renal I/R injury.